Neurocrine Biosciences announced that NBI‑1070770, an NR2B negative allosteric modulator licensed from Takeda, did not meet its primary endpoint in a Phase II major depressive disorder trial. The company confirmed the midstage failure in both independent reporting and a PR release, noting tolerability but no significant separation from placebo on the primary outcome. Neurocrine said its medical team will analyze the dataset for signals that might guide next steps, but the program’s immediate prospects have dimmed. The result represents the latest disappointment from assets licensed from Takeda to Neurocrine, following earlier midstage failures in schizophrenia and anhedonia programs. Investors pared expectations for the program; Neurocrine emphasized ongoing work on other psychiatry assets, including osavampator, which remains in later development.